(Q38153086)

29 August 2017

title

When should FDG-PET be used in the modern management of lymphoma? (English)

1 reference

29 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Nabegh George Mikhaeel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

17 October 2013

1 reference

British Journal of Haematology

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

315-328

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24131306%20AND%20SRC:MED&resulttype=core&format=json

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

2 June 2020

cites work

1 reference

Limitations of PET for imaging lymphoma

21 January 2018

1 reference

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

21 January 2018

1 reference

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma

21 January 2018

1 reference

In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.

21 January 2018

1 reference

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

21 January 2018

1 reference

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

21 January 2018

1 reference

18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.

21 January 2018

1 reference

The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.

21 January 2018

1 reference

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

21 January 2018

1 reference

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

21 January 2018

1 reference

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

21 January 2018

1 reference

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

21 January 2018

1 reference

Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy.

21 January 2018

1 reference

Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.

21 January 2018

1 reference

Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.

21 January 2018

1 reference

Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.

21 January 2018

1 reference

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

21 January 2018

1 reference

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

21 January 2018

1 reference

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma

21 January 2018

1 reference

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

21 January 2018

1 reference

Characterization of T-cell lymphomas by FDG PET/CT.

21 January 2018

1 reference

Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read.

21 January 2018

1 reference

Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma

21 January 2018

1 reference

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis

21 January 2018

1 reference

Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?

21 January 2018

1 reference

Limitations of CT during PET/CT.

21 January 2018

1 reference

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

21 January 2018

1 reference

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

21 January 2018

1 reference

Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?

21 January 2018

1 reference

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

21 January 2018

1 reference

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

21 January 2018

1 reference

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

21 January 2018

1 reference

Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

21 January 2018

1 reference

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer

21 January 2018

1 reference

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

21 January 2018

1 reference

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

21 January 2018

1 reference

Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials.

21 January 2018

1 reference

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

21 January 2018

1 reference

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

21 January 2018

1 reference

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

21 January 2018

1 reference

CT and PET/CT findings of T-cell lymphoma.

21 January 2018

1 reference

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

21 January 2018

1 reference

Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate

21 January 2018

1 reference

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

21 January 2018

1 reference

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

21 January 2018

1 reference

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

21 January 2018

1 reference

Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis

21 January 2018

1 reference

Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

21 January 2018

1 reference

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

21 January 2018

1 reference

Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

21 January 2018

1 reference

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

21 January 2018

1 reference

Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?

21 January 2018

1 reference

Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.

21 January 2018

1 reference

Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma.

21 January 2018

1 reference

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

21 January 2018

1 reference

SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma

21 January 2018

1 reference

(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients

21 January 2018

1 reference

Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma

21 January 2018

1 reference

Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.

21 January 2018

1 reference

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

21 January 2018

PET in T-Cell Lymphoma.

1 reference

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

21 January 2018

1 reference

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients

21 January 2018

1 reference